胆管癌新药英菲格拉替尼效果怎么样？正确用法是什么？

Infigratinib, an oral FGFR1-3 selective inhibitor, will be launched in the United States in May 2021. The drug is developed and produced by BridgeBio Pharma and is mainly used to treat cholangiocarcinoma. Cholangiocarcinoma is a malignant tumor, and most patients are diagnosed at an advanced stage with a very poor prognosis. The launch of Infigratinib has brought hope to patients with cholangiocarcinoma. Today, let’s learn more about the effect of Infigratinib in detail? What is the correct usage?

A phase 2, multi-center, single-group trial used infigratinib as third-line or above treatment for patients with FGFR2 fusion-positive cholangiocarcinoma. 71 patients were orally administered 125 mg once daily for 21 days, with a 28-day cycle. The median PFS of patients treated with infigratinib was 6.77 months; in the case of second-line treatment, the median PFS of patients was 4.63 months. For patients who received third-line or above treatment, the objective response rate of infigratinib was 21.6%. In other words, infigratinib has greater benefits in PFS and ORR in patients with third-line or above FGFR2 fusion cholangiocarcinoma, and its safety is tolerable.

So, what is the correct usage of Infigratinib? It is 125 mg. Before taking the drug, it is necessary to determine whether there is FGFR2 gene fusion or rearrangement. If it does not exist, the drug is not allowed to be taken. Infigratinib was administered continuously for 21 days and stopped for 7 days. A treatment cycle was 28 days, and it was taken orally once a day. Patients need to take the medicine at a fixed time period and on an empty stomach, that is, at least 1 hour before each meal or 2 hours after each meal. Infigratinib capsules must not be crushed, chewed or dissolved. If the dosage needs to be adjusted for patients with liver and kidney function impairment, the dosage must be adjusted according to the doctor's advice. Do not increase or decrease the dosage without permission to avoid intolerance reactions and affect the original condition.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: